What to Expect at the 7th Glioblastoma Drug Development Summit - the Leading Forum for Glioblastoma Drug Development
Regardless of your stage of development, modality or company size, the upcoming Glioblastoma Drug Development Summit will be the essential event for advancing GBM therapies.
With recent milestones, including Mustang Bio’s orphan drug designation for its CAR-T therapy and SurVaxM’s continued Phase IIb success, reigniting momentum in glioblastoma drug development, this premier summit will drive critical discussions:
- Using AI, multiomics, and molecular subtyping are informing patient stratification and accelerating clinical strategies in glioblastoma drug development.
- Exploring the use of K9 models, patient-derived organoids, and engineered rodent models to support successful IND applications for GBM therapies
- Delving into innovative glioblastoma treatment modalities such as tumor-fighting gene therapies, cancer vaccines, CAR-T, and ADC approaches
- Advancing patient-centric trial designs that ensure critically ill glioblastoma patients receive cutting-edge therapies without placebo arms
- Navigating the challenging investment and partnership landscape in glioblastoma and understand the key drivers behind funding and in-licensing decisions
Overcoming the Brain’s Immunosuppressive Environments with Cell Therapy Approaches for Breakthrough GBM Treatments
Following Kite Pharma and Gilead’s impressive breakthrough in a CAR-T treatment for Glioblastoma, cell therapy approaches are becoming a new source oh hope for the GBM field. This session will see data from Kite/Gileads’s trial being shared, along with novel platforms and autologous approaches for cell therapy in GBM.
With expert insights from:
Overcoming the Brain’s Immunosuppressive Environments with Cell Therapy Approaches for Breakthrough GBM Treatments
Following Kite Pharma and Gilead’s impressive breakthrough in a CAR-T treatment for Glioblastoma, cell therapy approaches are becoming a new source oh hope for the GBM field. This session will see data from Kite/Gileads’s trial being shared, along with novel platforms and autologous approaches for cell therapy in GBM.
With expert insights from:
- Ulrike Gerdemann, Principal Investigator & Physician Scientist, Dana-Faber Cancer Institute & Harvard Medical School
- Aaron Edwards, Co-Founder & Chief Executive Officer, KiraGen Bio
- Carlo Russo, Chief Medical Officer, Genenta Science
Navigating the Investment & Partnerships Landscape in GBM & Matchmaking Roundtables
Join Merck, Modifi Bio, Google Ventures, RA Capital Management, Brain Tumor Investment Fund and White Lion Capital to discuss key milestones, translatable models and biomerkaers that are prioritized by investors to mitigate the high risk nature of GBM drug development.
Network with:
- Carla Bauer, Director - Oncology Search & Evaluation, Business Development & Licensing, Merck & Co
- Ranjit Bindra, Founder, Modifi Bio
- Jonathan Pritz, Investment Director – Venture, RA Capital Management
- Yash Thukral, Managing Director, White Lion Capital
- John Higgins, Managing Director, Brain Tumour Investment Fund
- Sam Blackman, Entrepreneur-in-Residence, Google Ventures
Gain Exposure to Investors by Taking Part in the Pitch Slam
Our tech slam welcomes the opportunity for 4 biotechs eager to promote their technology to our investors through 15-minute presentations with a guaranteed audience of our investment and pharma business development speakers. Contact sponsor@hansonwade.com to learn more.
Explore the Innovative Use of AI in Reducing Development Time & Improving Trial Enrolment
Hear from how innovative applications of AI are reducing bench to bedside timelines and improving clinical experience for patients, practitioners, and families.
Hear from:
- Jason Binder, Head of Patient Experience, Pathos AI
- Panna Sharma, Chief Executive Officer & President, Lantern Pharma
Explore the Full Event Guide
- 90+ industry attendees
- 25+ World Class Speaker
- 6 deep-dive workshops, covering end-to-end drug development
- 8+ Hours on Networking
- The world’s only industry-led forum focussed on Glioblastoma drug development
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.